期刊
FUTURE VIROLOGY
卷 5, 期 5, 页码 555-574出版社
FUTURE MEDICINE LTD
DOI: 10.2217/FVL.10.48
关键词
AAVSI; adeno-associated virus; cell therapy; gene therapy; targeted gene addition
类别
资金
- Medical Research Council [G1001764] Funding Source: Medline
- NIGMS NIH HHS [R01 GM071023-04, R01 GM071023] Funding Source: Medline
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071023] Funding Source: NIH RePORTER
Adeno-associated viruses (AAV) are widely spread throughout the human population, yet no pathology has been associated with infection. This fact, together with the availability of simple molecular techniques to alter the packaged viral genome, has made AAV a serious contender in the search for an ideal gene therapy delivery vehicle. However, our understanding of the intriguing features of this virus is far from exhausted and it is likely that the mechanisms underlying the viral lifestyle will reveal possible novel strategies that can be employed in future clinical approaches. One such aspect is the unique approach AAV has evolved in order to establish latency. In the absence of a cellular milieu that will support productive viral replication, wild-type AAV can integrate its genome site specifically into a locus on human chromosome 19 (termed AAVSI), where it resides without apparent effects on the host cell until cellular conditions are changed by outside influences, such as adenovirus superinfection, which will lead to the rescue of the viral genome and productive replication. This article will introduce the biology of AAV, the unique viral strategy of targeted genome integration and address relevant questions within the context of attempts to establish therapeutic approaches that will utilize targeted gene addition to the human genome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据